课题基金基金详情
基于T淋巴细胞活性可视化监测的序贯性肿瘤免疫联合治疗策略
结题报告
批准号:
81972877
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
黄玉辉
依托单位:
学科分类:
肿瘤综合治疗
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
黄玉辉
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
肿瘤免疫治疗的新近进展为人类战胜恶性肿瘤带来了希望,但仍面临着一些严峻的挑战,如反应率低和缺乏可靠的疗效评估手段。我们的前期研究发现:免疫检查点疗法可诱导肿瘤血管正常化,且正常化的程度与其疗效呈正相关。据此,我们提出科学假说:肿瘤血管功能的影像学信号可转化为对肿瘤浸润免疫细胞活性的实时监测,并用于建立新型的序贯性肿瘤免疫联合治疗。为此,我们将在结肠癌病人中验证免疫检查点疗法可诱导肿瘤血管正常化;通过阐明免疫检查点疗法对肿瘤血管的作用机制,建立关键免疫效应成份,如CD8+ T细胞、IFNγ、CXCL9,与肿瘤血管功能的可视化关联;然后在对免疫检查点疗法耐受的肿瘤模型,探索基于实时监测T细胞活性的新型高效的序贯性免疫联合治疗方案。本项目的顺利完成将建立一种全新的基于肿瘤血管功能的可视化监测肿瘤浸润免疫细胞活性的方法,并为构建新型的肿瘤精准免疫治疗策略提供理论依据,造福癌症患者。
英文摘要
Cancer immunotherapy has brought a hope to cure malignant cancers, but only in a small fraction of cancer patients. Low response rates and lack reliable approaches to evaluate and predict the therapeutic efficacy, represent two major challenges currently facing immune checkpoint blockade therapy (ICB). Our recent studies found that ICB induces tumor vascular normalization and the increased vessel perfusion positively correlates with its therapeutic efficacy. Thus, we hypothesized that the function status of tumor blood vessels can be served as a novel visible biomarker to predict the activities of tumor-infiltrating immune cells stimulated by ICB. To test this hypothesis, we will confirm that ICB can induce tumor vascular normalization in colon cancer patients. Second, we will investigate the molecular mechanism mediated the effects of ICB on the formation and function of tumor blood vessels, and then analyze the dynamic relationship between the function status of tumor blood vessels and key tumor-infiltrating immune effectors, including CD8+ T cells, IFNγ, and CXCL9. Finally, we will explore rationally scheduled combinational ICB to overcome the resistance of a tumor to ICB. The successful completion of this project may identify a novel biomarker to authentically reflect the activities of tumor-infiltrating immune effector cells according to tumor vessel function, and establish a new strategy to realize precision cancer immunotherapy based on noninvasive biomarkers. These findings may guide to develop more potent combinational cancer immunotherapy in the clinic and bring long-term survival benefits to more patients suffering from cancers.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1073/pnas.2020057118
发表时间:2021-06-01
期刊:PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
影响因子:11.1
作者:Zhang, Naidong;Yin, Rongping;Huang, Yuhui
通讯作者:Huang, Yuhui
DOI:10.3389/fimmu.2022.937924
发表时间:2022
期刊:Frontiers in immunology
影响因子:7.3
作者:
通讯作者:
DOI:10.1155/2023/5867047
发表时间:2023
期刊:JOURNAL OF IMMUNOLOGY RESEARCH
影响因子:4.1
作者:Zhang, Yan;Gao, Jiayan;He, Yan;Qi, Ziwei;Qian, Long;Chen, Wanpei;Xu, Haiyan;Yue, Yanhua;Mao, Xunyuan;Guo, Shuxin;Zhou, Yan;Zhou, Shuru;Qin, Songbing;Zhang, Xueguang;Huang, Yuhui
通讯作者:Huang, Yuhui
DOI:10.20892/j.issn.2095-3941.2021.0507
发表时间:2021
期刊:Cancer Biology and Medicine
影响因子:--
作者:Wu Qiaozhen;Huang Yuhui
通讯作者:Huang Yuhui
肿瘤内皮细胞免疫检查点的作用机制与精准免疫治疗策略
  • 批准号:
    82150106
  • 项目类别:
    国际(地区)合作与交流项目
  • 资助金额:
    260万元
  • 批准年份:
    2021
  • 负责人:
    黄玉辉
  • 依托单位:
嗜酸性粒细胞介导的CTLA4抗体对乳腺癌的抑制作用
  • 批准号:
    81673004
  • 项目类别:
    面上项目
  • 资助金额:
    62.0万元
  • 批准年份:
    2016
  • 负责人:
    黄玉辉
  • 依托单位:
吡非尼酮对肿瘤免疫微环境的作用机制研究
  • 批准号:
    81372245
  • 项目类别:
    面上项目
  • 资助金额:
    62.0万元
  • 批准年份:
    2013
  • 负责人:
    黄玉辉
  • 依托单位:
国内基金
海外基金